XUANTAI PHARMACEUTICAL: Collaboration Product Enzalutamide Tablets Approved for Market Launch

MetaMuskRat · 2026-03-15T05:16:17+00:00

Xuantai Pharmaceutical announces that its co-developed Enzalutamide Tablets have received market approval from the National Medical Products Administration, applicable to various prostate cancer patients, including those with metastatic hormone-sensitive and castration-resistant prostate cancer.

MetaMuskRat

2026-03-15 05:16:17

Abstract generation in progress

People’s Financial News, March 13 — Xuantai Pharmaceutical (688247) announced on March 13 that recently, the Enzalutamide tablets developed in collaboration with partners received the “Drug Registration Certificate” issued by the National Medical Products Administration, approving the product for market launch. Enzalutamide is an androgen receptor inhibitor. The approved indications are: for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC); for adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis; and for adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT), are asymptomatic or have mild symptoms, and have not received chemotherapy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.